Isoxazolidines as RIPK1 inhibitors and use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11897876
APP PUB NO 20230203027A1
SERIAL NO

17983883

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GENZYME CORPORATION450 WATER STREET CAMBRIDGE MA 02141

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Defossa, Elisabeth Frankfurt am Main, DE 64 519
Heinelt, Uwe Frankfurt am Main, DE 54 495
Matter, Hans Frankfurt am Main, DE 68 548
Mendez-Perez, Maria Frankfurt am Main, DE 18 105
Rackelmann, Nils Frankfurt am Main, DE 14 8
Ritter, Kurt Frankfurt am Main, DE 59 1606
Szillat, Hauke Frankfurt am Main, DE 7 19
Zech, Gernot Frankfurt am Main, DE 8 19

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 13, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 13, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 13, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00